Evidence Explorer / Evidence record
BOTANICALS & NATURAL PRODUCTS
Cannabinoids for refractory chemotherapy nausea
Conditional adjunctive option
Selected cannabinoid preparations may help refractory chemotherapy-related nausea and vomiting when added to appropriate antiemetics.
MS-N012 · Sources checked October 11, 2026 · Nausea and vomiting
What was studied?
People and setting: Adults with symptoms despite guideline-based antiemetics
Evidence basis: ASCO cannabis and cannabinoid guideline, 2024
What can we conclude?
The recommendation is weak and product-specific; it does not apply to all cannabis products or establish anticancer activity.
Safety and practical context
Discuss sedation, cognition, falls, driving and interactions; clinician-guided use is important.
Questions for the care team
- Does this evidence apply to my cancer, treatment and goal?
- Does the exact preparation or delivery method match the study?
- What benefit is plausible, what could go wrong, and what care must continue?
Sources
Connected reviews
Learn how to judge a study · Return to the evidence map
This is a concise evidence brief, not an exhaustive systematic review or a personal treatment recommendation. Evidence labels describe the named use; they are not formal GRADE ratings. A missing harm report does not establish safety.
